Mistral Pharma to sell units in private placement

By Devika Patel

Knoxville, Tenn., Feb. 27 - Mistral Pharma Inc. said it plans to conduct a private placement of units.

The company will sell units of one common share and a half-share warrant. Each whole warrant will be exercisable for two years.

Loewen, Ondaatje, McCutcheon Ltd. is the lead agent.

Proceeds will be placed in escrow pending completion of all conditions necessary for Mistral's planned business combination with a private U.S.-based specialty pharmaceutical company, including approval by Mistral shareholders and securing a minimum amount of financing through the private placement. In the event the combination is not completed, the escrowed funds will be returned to the subscribers.

Mistral is a pharmaceutical company in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.